Department of Endocrinology, Beijing Jishuitan Hospital, Beijing, China.
Department of Clinical Diabetes and Epidemiology, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Front Endocrinol (Lausanne). 2022 Jun 10;13:891718. doi: 10.3389/fendo.2022.891718. eCollection 2022.
Although insulin pump therapy is an important treatment modality for patients with type 1 diabetes, rates of pump use appear to vary broadly internationally. This study aimed to investigate the application of insulin pump therapy among patients with type 1 diabetes in China.
Data were collected from the Type 1 Diabetes Mellitus in China: Coverage, Costs and Care Study (3C Study). A total of 779 participants from this cross-sectional study were included. Multivariable logistic regression was used for data analysis.
The median (interquartile range) age at diagnosis of diabetes was 17 (10-28) years and the duration of diabetes was 4 (1-8) years. Among 779 patients, only 89 patients (11.4%) used an insulin pump to control blood glucose. A statistically significant difference was found in HbA1c favoring insulin pump therapy (8.3 ± 1.7% vs. 9.2 ± 2.6%) without obvious differences for severe hypoglycaemia. There were higher proportions of patients with no smoking, frequent daily intake of fruits and vegetables, and adequate self-blood glucose monitoring among patients with insulin pump therapy as compared to those using multiple daily insulin injections. Logistic regression analysis showed that younger age at diagnosis, longer duration of diabetes, higher education level of family members, and higher household income were associated with the use of an insulin pump.
Data from 3C Study demonstrated that only a minority of patients with type 1 diabetes in China utilize insulin pump therapy. Insulin pump therapy was associated with better blood glucose control and self-management. Patients with younger age at diagnosis and longer duration of diabetes, and patients with better socioeconomic status were more likely to use an insulin pump.
尽管胰岛素泵治疗是 1 型糖尿病患者的重要治疗方式，但泵的使用比例在国际上似乎存在很大差异。本研究旨在调查中国 1 型糖尿病患者胰岛素泵治疗的应用情况。
数据来自中国 1 型糖尿病：覆盖范围、成本和护理研究（3C 研究）。这项横断面研究共纳入 779 名参与者。采用多变量逻辑回归进行数据分析。
诊断糖尿病时的中位（四分位距）年龄为 17 岁（10-28 岁），糖尿病病程为 4 年（1-8 年）。在 779 名患者中，仅有 89 名（11.4%）患者使用胰岛素泵控制血糖。胰岛素泵治疗组的 HbA1c 明显更低（8.3±1.7% vs. 9.2±2.6%），低血糖严重程度无明显差异。与多次胰岛素注射组相比，胰岛素泵治疗组患者中不吸烟、经常摄入水果和蔬菜、以及自我血糖监测更充分的比例更高。Logistic 回归分析显示，诊断年龄越小、糖尿病病程越长、家庭成员教育程度越高、家庭收入越高，与使用胰岛素泵相关。
3C 研究的数据表明，中国只有少数 1 型糖尿病患者使用胰岛素泵治疗。胰岛素泵治疗与更好的血糖控制和自我管理相关。诊断年龄较小、病程较长、社会经济状况较好的患者更有可能使用胰岛素泵。
